A detailed history of Pdt Partners, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 123,031 shares of RNA stock, worth $5.03 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
123,031
Previous 91,600 34.31%
Holding current value
$5.03 Million
Previous $828,000 279.11%
% of portfolio
0.31%
Previous 0.09%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.16 - $25.52 $287,907 - $802,119
31,431 Added 34.31%
123,031 $3.14 Million
Q4 2023

Feb 14, 2024

BUY
$4.87 - $9.37 $446,092 - $858,291
91,600 New
91,600 $828,000
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $704,521 - $1.59 Million
70,032 New
70,032 $1.55 Million
Q2 2022

Aug 15, 2022

SELL
$11.18 - $20.5 $371,153 - $680,559
-33,198 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$14.2 - $23.78 $57,027 - $95,500
-4,016 Reduced 10.79%
33,198 $613,000
Q4 2021

Feb 14, 2022

BUY
$20.4 - $28.66 $57,405 - $80,649
2,814 Added 8.18%
37,214 $885,000
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $118,040 - $163,865
6,500 Added 23.3%
34,400 $847,000
Q2 2021

Aug 16, 2021

BUY
$19.62 - $29.26 $547,398 - $816,354
27,900 New
27,900 $689,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.13B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.